LENZ Therapeutics (LENZ) Total Non-Current Liabilities (2020 - 2024)
LENZ Therapeutics (LENZ) posted quarterly Total Non-Current Liabilities of $11.2 million for Q4 2024, down 42.69% year-over-year from $19.6 million in Q1 2024, and up 29.52% quarter-over-quarter from $8.7 million in Q3 2024.
LENZ Therapeutics (LENZ) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Total Non-Current Liabilities for 5 consecutive years, with $11.2 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Total Non-Current Liabilities fell 42.69% year-over-year to $11.2 million; the TTM figure through Dec 2024 stood at $11.2 million (down 42.69% YoY), while the FY2024 annual figure was $11.2 million, down 42.69% from the prior year.
- Total Non-Current Liabilities rose to $11.2 million in Q4 2024 per LENZ's latest filing, from $8.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $62.9 million in Q2 2023 and bottomed at $7.9 million in Q2 2021.
- Historically, Total Non-Current Liabilities has averaged $23.6 million across 5 years, with a median of $17.0 million in 2021.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 289.41% — and 2024, when it slumped 86.07%.
- LENZ Therapeutics' Total Non-Current Liabilities stood at $32.0 million in 2020, then sank by 44.03% to $17.9 million in 2021, then decreased by 17.53% to $14.8 million in 2022, then soared by 32.35% to $19.6 million in 2023, then tumbled by 42.69% to $11.2 million in 2024.
- Business Quant data shows LENZ's Total Non-Current Liabilities at $11.2 million in Q4 2024, $8.7 million in Q3 2024, and $9.6 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | LENZ Therapeutics | 148.71 Mn | 148.71 Mn | 5.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 11.22 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 9.64 Mn |
| Mar 31, 2024 | 19.04 Mn |
| Dec 31, 2023 | 19.58 Mn |
| Sep 30, 2023 | 62.21 Mn |
| Jun 30, 2023 | 62.90 Mn |
| Mar 31, 2023 | 32.90 Mn |
| Dec 31, 2022 | 14.79 Mn |
| Sep 30, 2022 | 15.98 Mn |
| Dec 31, 2021 | 17.94 Mn |
| Sep 30, 2021 | 15.96 Mn |
| Jun 30, 2021 | 7.86 Mn |
| Dec 31, 2020 | 32.05 Mn |